Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | ALDH1A3 | P47895 | 5/20 | 0.42 |
| ▸ | ALDH3A1 | P30838 | 5/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983658 | 0.83 | TSHR (0.32) | LMNAMAPTKMT2A | |
| SCHEMBL2721191 | 0.81 | ALDH1A1 (0.42) | ALDH1A1 | |
| SCHEMBL340725 | 0.79 | ALDH1A1 (0.39) | ALDH1A1ALDH1A3ALDH3A1CYP2A6LMNA | |
| SCHEMBL15648671 | 0.77 | BDKRB2 (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL15648819 | 0.77 | BDKRB2 (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL8758590 | 0.77 | ALDH1A1 (0.38) | ALDH1A1MAPTKMT2A | |
| SCHEMBL2202198 | 0.77 | CYP19A1 (0.42) | MAPT | |
| SCHEMBL2202201 | 0.77 | CYP19A1 (0.42) | MAPT | |
| SCHEMBL1452840 | 0.75 | HTT (0.38) | ALDH1A1LMNAHPGDSMN1; SMN2KMT2A | |
| SCHEMBL5787759 | 0.74 | MAPT (0.41) | ALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177580-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2025-06-05 | — | — | US | disclosed |
| US-12233137-B1 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250057996-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | DUKE UNIVERSITY | 2025-02-20 | — | — | US | disclosed |
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| EP-3749653-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | The Johns Hopkins University (US) | 2020-12-16 | — | — | EP | disclosed |
| CN-112020497-A | PSMA-targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | 约翰霍普金斯大学 | 2020-12-01 | — | — | CN | disclosed |
| WO-2019157037-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-2509638-B1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LTD (GB) | 2016-01-28 | — | — | US | disclosed |
| US-5869465-A | BINDING TO CELL SURFACE RECEPTORS AND AFFECTING THEIR TRAFFICKING PATHWAY FOR THE TREATMENT AND DIAGNOSIS OF DISORDERS IN WARM-BLOODED ANIMALS | RECEPTAGEN CORPORATION (US) | 1999-02-09 | — | — | US | disclosed |
| US-5840712-A | TARGETS AND LINKERS | RECEPTAGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| US-5783679-A | Purine nucleoside modifications by palladium catalyzed methods and oligonucleotides containing same | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-07-21 | — | — | US | disclosed |
| US-5746997-A | Radiohalogenation of oligonucleotides via trialkylstannylaryl conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| US-5739287-A | BOUND ALSO TO A RECEPTOR MODULATING AGENT TO IMPEDE CELL SURFACE RECEPTOR TRAFFICKING PATHWAYS BY INHIBITING THE RECYCLING OF RECEPTORS TO THE CELL SURFACE; ANTITUMOR AND -CARCINOGENIC AGENTS; LEUKEMIA | UNIVERSITY OF WASHINGTON (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0828750-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NeXstar Pharmaceuticals, Inc. (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5719273-A | GENETIC ENGINEERING | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1996038460-A1 | PALLADIUM CATALYZED NUCLEOSIDE MODIFICATION METHODS USING NUCLEOPHILES AND CARBON MONOXIDE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-05 | — | — | WO | disclosed |
| US-5580972-A | DISPLACEMENT OF HALOGEN LEAVING GROUP ATTACHED TO PURINE RING WITH ORGANOTIN COMPOUND IN PRESENCE OF PALLADIUM CATALYST | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1996016972-A1 | PURINE NUCLEOSIDE MODIFICATIONS BY PALLADIUM CATALYZED METHODS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220493-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA3, PSMA2 | ALDH1A1 2489/4885ALDH1A3 1850/4885ALDH3A1 1901/4885 |
| US-20160022846-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | ALDH1A1 3531/4885ALDH1A3 3844/4885ALDH3A1 2885/4885 |
| US-12233137-B1 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | PSMA1, PSMA2, PSMA3 | ALDH1A1 2505/4885ALDH1A3 1884/4885ALDH3A1 1953/4885 |
| US-20250057996-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA2, PSMA3 | ALDH1A1 2505/4885ALDH1A3 1884/4885ALDH3A1 1953/4885 |
| US-11813340-B2 | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy | PSMA1, PSMA3, PSMA2 | ALDH1A1 2489/4885ALDH1A3 1850/4885ALDH3A1 1901/4885 |
| US-20250177580-A1 | PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY | PSMA1, PSMA2, PSMA3 | ALDH1A1 2505/4885ALDH1A3 1884/4885ALDH3A1 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.